Roche's Genentech Inc. unit has figured
out why different MEK inhibitors exhibit
varying efficacy against BRAF- or K-Ras-driven cancers,
which could help in the design of next-generation inhibitors with improved
therapeutic indexes.1 Genentech already has one inhibitor for each
kind of tumor in clinical trials.
In addition to helping fine-tune patient selection, the study's
mechanistic insights could spur the development of MEK inhibitors with improved
Boettner, B. SciBX 6(36); doi:10.1038/scibx.2013.981
Published online Sept. 19, 2013
1. Hatzivassiliou, G. et
al. Nature; published online Aug. 11, 2013; doi:10.1038/nature12441
Contact: Marcia Belvin, Genentech Inc., South San Francisco, Calif.
Contact: Georgia Hatzivassiliou, same affiliation as above
2. Solit, D.B. et al.
Nature 439, 358-362 (2006)
3. Pratilas, C.A. et
al. Proc. Natl. Acad. Sci. USA 106, 4519-4524 (2009)
4. Poulikakos, P.I. &
Rosen, N. Cancer Cell 19, 11-15 (2011)
AND INSTITUTIONS MENTIONED
Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo.
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Broad Institute of MIT and Harvard, Cambridge, Mass.
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan
Dana-Farber Cancer Institute, Boston, Mass.
Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif.
Genentech Inc., South San Francisco, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Harvard Medical School, Boston, Mass.
Japan Tobacco Inc. (Tokyo:2914; Osaka:2914), Tokyo, Japan
Merck KGaA (Xetra:MRK), Darmstadt, Germany
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
The University of North Carolina at Chapel Hill School of
Medicine, Chapel Hill,